These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 12848973)

  • 21. Distinct characteristics of antibody responses against factor VIII in healthy individuals and in different cohorts of hemophilia A patients.
    Whelan SF; Hofbauer CJ; Horling FM; Allacher P; Wolfsegger MJ; Oldenburg J; Male C; Windyga J; Tiede A; Schwarz HP; Scheiflinger F; Reipert BM
    Blood; 2013 Feb; 121(6):1039-48. PubMed ID: 23243272
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adenovirus-mediated factor VIII gene expression results in attenuated anti-factor VIII-specific immunity in hemophilia A mice compared with factor VIII protein infusion.
    Bristol JA; Gallo-Penn A; Andrews J; Idamakanti N; Kaleko M; Connelly S
    Hum Gene Ther; 2001 Sep; 12(13):1651-61. PubMed ID: 11535168
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Management of spontaneous inhibitors in children with porcine factor VIII.
    Kobrinsky NL; Stegman D; Sjolander D
    Haemophilia; 2002 Jan; 8 Suppl 1():1-4; discussion 28-32. PubMed ID: 11882074
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Characterization of factor VIII antibody epitopes from haemophilia A patients using cellulose bound FVIII peptide libraries].
    Albert T; Lange S; Oldenburg J; Graw J; Schramm W; Hanfland P; Brackmann HH; Schwaab R
    Hamostaseologie; 2003 Feb; 23(1):13-7. PubMed ID: 12567194
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Induction of human factor VIII inhibitors in rats by immunization with human recombinant factor VIII: a small animal model for humans with high responder inhibitor phenotype.
    Jarvis MA; Levin LG; Harrison JA; DePianto DJ; Suzuki CM; Ziaja CL; Brown JE; Jolly KW; Reisner HM; Abildgaard CF; Powell JS
    Thromb Haemost; 1996 Feb; 75(2):318-25. PubMed ID: 8815584
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Limit of detection and threshold for positivity of the Centers for Disease Control and Prevention assay for factor VIII inhibitors.
    Miller CH; Boylan B; Shapiro AD; Lentz SR; Wicklund BM;
    J Thromb Haemost; 2017 Oct; 15(10):1971-1976. PubMed ID: 28795528
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New protocol for immune tolerance induction in acquired hemophilia.
    Nemes L; Pitlik E
    Haematologica; 2000 Oct; 85(10 Suppl):64-8. PubMed ID: 11187874
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rapid acquisition of immunologic tolerance to factor VIII and disappearance of anti-factor VIII IgG4 after prophylactic therapy in a hemophilia A patient with high-titer factor VIII inhibitor.
    Moorehead PC; Thibeault L; Tuttle A; Grabell J; Dwyre L; Silva M; James P; Lillicrap D
    J Pediatr Hematol Oncol; 2015 May; 37(4):e220-2. PubMed ID: 25411864
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Proteolytic antibodies activate factor IX in patients with acquired hemophilia.
    Wootla B; Christophe OD; Mahendra A; Dimitrov JD; Repessé Y; Ollivier V; Friboulet A; Borel-Derlon A; Levesque H; Borg JY; Andre S; Bayry J; Calvez T; Kaveri SV; Lacroix-Desmazes S
    Blood; 2011 Feb; 117(7):2257-64. PubMed ID: 21131590
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical evaluation of recombinant factor VIII preparation (Kogenate) in previously treated patients with hemophilia A: descriptive meta-analysis of post-marketing study data.
    Yoshioka A; Fukutake K; Takamatsu J; Shirahata A;
    Int J Hematol; 2006 Aug; 84(2):158-65. PubMed ID: 16926139
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Factor VIII inhibitor with catalytic activity towards factor VIII.
    Lacroix-Desmazes S; Sooryanarayana ; Moreau A; Horn MP; Kazatchkine MD; Kaveri SV
    Chem Immunol; 2000; 77():102-14. PubMed ID: 11706701
    [No Abstract]   [Full Text] [Related]  

  • 32. Immunological characterization of factor VIII autoantibodies in patients with acquired hemophilia A in the presence or absence of underlying disease.
    Matsumoto T; Shima M; Fukuda K; Nogami K; Giddings JC; Murakami T; Tanaka I; Yoshioka A
    Thromb Res; 2001 Dec; 104(6):381-8. PubMed ID: 11755947
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anti-factor VIII antibodies: a 2005 update.
    Lavigne-Lissalde G; Schved JF; Granier C; Villard S
    Thromb Haemost; 2005 Oct; 94(4):760-9. PubMed ID: 16270627
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Blockade of CD40/CD40 ligand interactions prevents induction of factor VIII inhibitors in hemophilic mice but does not induce lasting immune tolerance.
    Reipert BM; Sasgary M; Ahmad RU; Auer W; Turecek PL; Schwarz HP
    Thromb Haemost; 2001 Dec; 86(6):1345-52. PubMed ID: 11776297
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In silico prediction of FVIII epitopes recognised by natural autoantibodies in polyvalent immunoglobulin concentrates.
    Di Giambattista M; Branckaert T; Hougardy V; Kemball-Cook G; Laub R
    Mol Immunol; 2007 Mar; 44(8):1903-13. PubMed ID: 17113150
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immune response to FVIII in hemophilia A: an overview of risk factors.
    Ghosh K; Shetty S
    Clin Rev Allergy Immunol; 2009 Oct; 37(2):58-66. PubMed ID: 19148784
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Circulating factor VIII immune complexes in patients with type 2 acquired hemophilia A and protection from activated protein C-mediated proteolysis.
    Nogami K; Shima M; Giddings JC; Hosokawa K; Nagata M; Kamisue S; Suzuki H; Shibata M; Saenko EL; Tanaka I; Yoshioka A
    Blood; 2001 Feb; 97(3):669-77. PubMed ID: 11157483
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Maternally transferred anti-factor VIII IgG reduce the anti-factor VIII humoral immune response in factor VIII-deficient mice.
    Meslier Y; André S; Teyssandier M; Kaveri SV; Lacroix-Desmazes S
    Immunology; 2010 Dec; 131(4):549-55. PubMed ID: 20673239
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Continuous infusion of porcine factor VIII in the management of patients with factor VIII inhibitors.
    Rubinger M; Houston DS; Schwetz N; Woloschuk DM; Israels SJ; Johnston JB
    Am J Hematol; 1997 Oct; 56(2):112-8. PubMed ID: 9326353
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nijmegen-Bethesda assay to measure factor VIII inhibitors.
    Duncan E; Collecutt M; Street A
    Methods Mol Biol; 2013; 992():321-33. PubMed ID: 23546724
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.